Trial Profile
Single Center, Open-label, Accelerated Titration, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre-efficacy of BVAC-B in Patients With Progressive or Recurrent HER2/Neu Positive Gastric Cancer After Failure to Standard Care
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs BVAC-B (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; First in man
- Sponsors Cellid Company
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 19 Feb 2020 Status changed from recruiting to completed.
- 21 Aug 2018 Status changed from not yet recruiting to recruiting.